Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Biotechnology

Healthcare
$8.44 +3.04%

+$0.26 today

Market cap
$547.12M
Beta
1.80
P/E (TTM)
-1.7
EPS (TTM)
-$5.11
52W Low $5.37High $17.58

Volume 2.36M

Average 1.24M

DNA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Ginkgo Bioworks Holdings, Inc.NYSE: DNA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $76.06M (cash outflow) fell 16.4% year over year, ahead of the -36.9% change in trailing-twelve-month net income. Sequentially, it fell 5.8% from the prior quarter. Over 3 fiscal years it compounded at -47.0% a year.

Context

  • Net income amounted to 183.8% of revenue in FY2025, down 57.1 pp from a year earlier.
  • Net income grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 2 analysts of -$244.06M (-22.0%) for the fiscal year ending Dec 2026, a step up from the -42.8% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$76.06M-5.8% QoQ
Last fiscal yearDec 2025
-$312.76M-42.8% YoY
LTMMar 2026
-$297.87M-36.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.4%-5.1%+11.3 pp
1 year-42.8%-22.0%+20.9 pp
3-year CAGR-47.0%-16.9%+30.2 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(312.76M) USD
Year-over-year change
+42.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How DNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -36.9% is the 8th highest of 10, against a peer median of +37.9%.
  • Net income amounts to 210.8% of revenue for DNA, versus a peer median of 170.5%.
DNA Competitors
Net Income for DNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$442.72M USD-23.4%—676.0%
MGTXMeiraGTx Holdings plcLTM Mar 2026$328.6M USD+96.4%-4.1%412.0%
REPLReplimune Group, Inc.LTM Dec 2025$314.85M USD+37.9%+28.0%—
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$297.87M USD-36.9%-47.0%210.8%
ARVNArvinas, Inc.LTM Mar 2026$221.3M USD+374.9%-34.1%247.5%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$220.54M USD-44.5%-0.4%58.2%
VALNValneva SELTM Mar 2026€146.23M EUR+81.9%-7.0%93.5%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$145.24M USD+14.0%+65.2%—
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$145.1M USD+80.3%+49.3%—
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$93.67M USD-68.6%—44.9%
Peer median (excluding DNA) —+37.9%-0.4%170.5%

Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.84B)(2.11B)(892.87M)(547.03M)(312.76M)
Depreciation & Amortization29.08M42.55M71.55M63.02M58.99M
Deferred Income Tax30.21M(14.61M)(801K)(936K)(1.36M)
Stock-Based Compensation1.61B1.93B229.88M112.34M81.55M
Change in Working Capital(61.54M)(37.01M)29.84M(89.67M)(44.09M)
Accounts Receivables(114.09M)55.02M50.07M(4.73M)(1.47M)
Inventory(626K)164K000
Accounts Payables(2.25M)(10.84M)(1.18M)4.77M(2.99M)
Other Working Capital55.43M(81.35M)(19.05M)(89.72M)(39.62M)
Other Non-Cash Items(20.95M)(67.4M)266.9M142.69M46.62M
Operating Cash Flow(253.82M)(252.2M)(295.5M)(319.59M)(171.06M)
Capital Expenditures(56.52M)(52.27M)(40.8M)(62.54M)(7.67M)
Acquisitions (Net)(12.04M)26.65M(38.55M)(5.4M)0
Purchases of Investments(5M)(3.69M)00(418.63M)
Sales of Investments0004.52M185.38M
Other Investing Activities304K(38.08M)(1.34M)1.19M624K
Investing Cash Flow(73.26M)(67.39M)(80.69M)(62.24M)(240.29M)
Debt Repayment(1.12M)(1.24M)(1.3M)(897K)(354K)
Common Stock Issued099.3M080K19.47M
Common Stock Repurchased(25M)0(23K)00
Dividends Paid00000
Other Financing Activities1.56B(2.73M)(1.43M)(922K)(1.34M)
Financing Cash Flow1.53B95.34M(3.22M)(1.74M)17.78M
Effect of Forex Changes(19K)908K(588K)(281K)395K
Net Change in Cash1.21B(223.35M)(380M)(383.84M)(393.18M)
Free Cash Flow(310.34M)(304.47M)(336.3M)(382.13M)(178.72M)

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Intrinsic Alpha fair value

Locked

Current Price

$8.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.